Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain receive the 2025 Merkin Prize at the Broad Institute for chimeric antigen receptor (CAR) T-cell therapy

Carl June, Bruce Levine, Isabelle Rivière, and Michel Sadelain receive the 2025 Merkin Prize at the Broad Institute for chimeric antigen receptor (CAR) T-cell therapy

This groundbreaking form of personalized cancer immunotherapy has had remarkable success — more than 45,000 cancer patients worldwide have been treated with CAR T-cell therapy, extending their lives and, in many cases, delivering complete and sustained remissions.